Explore Annogen’s News
Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
PRESS RELEASE Amsterdam, 30 November 2021 Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants. Annogen...
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence...
Collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA.
PRESS RELEASE Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence...
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, and KeyGene, the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate...
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Amsterdam, December 2019 Annogen BV is an Amsterdam based biotech company focussed on functional genome annotation using its proprietary SuRE technology. Its sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and...
